Allopurinol has been the workhorse of gout treatment for decades, and most patients reach target urate on it without trouble. The patients who don't are often ABCG2 reduced-function carriers. Q141K carriers tend to need higher doses or a switch to a different urate-lowering drug.
Allopurinol can cause severe hypersensitivity reactions including Stevens-Johnson syndrome, particularly in carriers of the HLA-B*58:01 allele (most common in East Asian, South Asian, and African ancestry populations). Gene2Rx does not currently test HLA alleles. Any rash, fever, mucosal involvement, or unwell feeling in the first 8 to 12 weeks of allopurinol therapy requires immediate evaluation. Stop the drug and seek emergency care if widespread rash, blistering, or skin sloughing develops.
If your serum urate isn't below 6 mg/dL, the dose is probably too low. Most patients need 300 mg daily or higher to reach target. Doses above 300 mg are routine, particularly in the United States, where 'standard' allopurinol doses are often inadequate.
Purine-rich foods (red meat, organ meats, beer, certain seafood) raise uric acid, but for most patients dietary changes alone bring uric acid down by less than 1 mg/dL. Drug therapy is usually the lever that actually moves the needle.
Allopurinol is started low and titrated up over weeks to months. If you're early in titration, the urate isn't going to be at target yet, and that's expected. Patience matters.
ABCG2 is the gene Gene2Rx covers for allopurinol. It explains a meaningful share of why some patients don't reach urate target on standard doses.
ABCG2 is a transporter that moves urate out of cells. The Q141K variant (rs2231142) reduces transporter function. Carriers have higher baseline serum urate and a smaller response to standard allopurinol doses. The variant is most common in East Asian populations but is also present in other populations at meaningful frequencies.
ABCG2 reduced-function carriers may need higher allopurinol doses (often 600 to 800 mg daily) to reach target urate, or a switch to febuxostat. Febuxostat works through the same enzyme target but is less dependent on ABCG2-mediated urate transport.
Most useful when allopurinol is failing to bring urate to target despite reasonable dose escalation. Knowing your ABCG2 status helps your prescriber decide whether to push the dose higher or switch to a different drug.
Febuxostat works through the same enzyme target (xanthine oxidase) and tends to be similarly effective at lowering urate. It does not require ABCG2 transport, so it's often a good choice for ABCG2 reduced-function patients. Cardiovascular safety has been a concern in some trials, so it's typically reserved for patients who can't take allopurinol.
No. Gene2Rx does not currently test HLA alleles. HLA-B*58:01 is associated with severe allopurinol skin reactions and is offered as a separate test by clinical pharmacogenetic laboratories, particularly recommended for patients of East Asian, South Asian, or African ancestry before starting allopurinol.
If serum urate is consistently below 6 mg/dL, flares should reduce over months but can still happen during the initial mobilization of urate from joints. If urate is above 6 mg/dL, the dose is too low. NSAID or colchicine prophylaxis during the first 6 months of allopurinol is standard to reduce mobilization flares.
Find out how your DNA may influence your response to Allopurinol and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator